New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies

References

• Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer systematic review: combination therapy in combating cancer background. Oncotarget. 2017;8(23):38022–38043.
   PubMed Web of Science ®Google Scholar
• Yap TA, Omlin A, De Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol. 2013;31(12):1592–1605.
   PubMed Web of Science ®Google Scholar
• Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008;26(24):3950–3957.
   PubMed Web of Science ®Google Scholar
• Li X, Li X, Liu F, Li S, Shi D. Rational multitargeted drug design strategy from the perspective of a medicinal chemist. J Med Chem. 2021;64(15):10581–10605.
   PubMed Web of Science ®Google Scholar
• Zhang W, Pei J, Lai L. Computational multitarget drug design. J Chem Inf Model. 2017;57(3):403–412.
   PubMed Web of Science ®Google Scholar
• Lamtha T, Krobthong S, Yingchutrakul Y, Samutrtai P, Gerner C, Tabtimmai L, Choowongkomon K. A novel nanobody as therapeutics target for EGFR-positive colorectal cancer therapy: exploring the effects of the nanobody on SW480 cells using proteomics approach. Proteome Sci. 2022;20(1):9.
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181.
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313(5998):144–147.
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. 2008;21 Suppl 2:S16–S22.
   PubMed Web of Science ®Google Scholar
• Yin HL, Janmey PA. Phosphoinositide regulation of the actin cytoskeleton. Annu Rev Physiol. 2003;65(1):761–789.
   PubMedGoogle Scholar
• Kamath S, Buolamwini JK. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Med Res Rev. 2006;26(5):569–594.
   PubMed Web of Science ®Google Scholar
• Ali A, Al-Jandan B, Suresh C. The importance of ctokeratins in the early detection of oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2018;22(3):441.
   PubMedGoogle Scholar
• Raghavendra NM, Pingili D, Kadasi S, Mettu A, Prasad SVUM. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem. 2018;143:1277–1300.
   PubMed Web of Science ®Google Scholar
• Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem. 1998;273(20):11987–11990.
   PubMed Web of Science ®Google Scholar
• Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges. Mol Cancer. 2018;17(1):34.
   PubMedGoogle Scholar
• Naishima NL, Faizan S, Raju RM, et al. Design, synthesis, analysis, evaluation of cytotoxicity against MCF-7 breast cancer cells, 3D QSAR studies and EGFR, HER2 inhibition studies on Novel Biginelli 1,4-dihydropyrimidines. J Mol Struct. 2023;1277:1–23.
   Web of Science ®Google Scholar
• Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193–743197.
   PubMedGoogle Scholar
• Mohmmed EA, Ramadan SS, EL-Saiid AS, Shousha WG. Frequency and clinical features of over-expressed her2 in Egyptian breast cancer women patients. Egypt J Hosp Med. 2021;85(1):3431–3435.
   Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Williams CB, Phelps-Polirer K, Dingle IP, Williams CJ, Rhett MJ, Eblen ST, Armeson K, Hill EG, Yeh ES. HUNK phosphorylates EGFR to regulate breast cancer metastasis. Oncogene. 2020;39(5):1112–1124.
   PubMed Web of Science ®Google Scholar
• Chang JW-C, Huang C-Y, Fang Y-F, Chang C-F, Yang C-T, Kuo C-HS, Hsu P-C, Wu C-E. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: real-world data from Taiwan. Thorac Cancer. 2023;14(1):12–23.
   PubMed Web of Science ®Google Scholar
• Zhang L, Deng X-S, Meng G-P, Zhang C, Liu C-C, Chen G-Z, Jiang X-L, Zhao Q-C, Hu C. Design, synthesis and biological evaluation of a novel series of indole-3- carboxamide derivatives for cancer treatment as EGFR inhibitors. LDDD. 2018;15(1):70–83.
   Google Scholar
• Djukic M, Fesatidou M, Xenikakis I, Geronikaki A, Angelova VT, Savic V, Pasic M, Krilovic B, Djukic D, Gobeljic B, et al. In vitro antioxidant activity of thiazolidinone derivatives of 1,3-thiazole and 1,3,4-thiadiazole. Chem Biol Interact. 2018;286:119–131.
   PubMed Web of Science ®Google Scholar
• Ayati A, Emami S, Moghimi S, Foroumadi A. Thiazole in the targeted anticancer drug discovery. Future Med Chem. 2019;11(15):1929–1952.
   PubMed Web of Science ®Google Scholar
• Gümüş M, Yakan M, Koca I. Recent advances of thiazole hybrids in biological applications. Future Med Chem. 2019;11(15):1979–1998.
   PubMed Web of Science ®Google Scholar
• Sever B, Altıntop MD, Radwan MO, et al. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors. Eur J Med Chem. 2019;182:1–17.
   Web of Science ®Google Scholar
• Keating GM. Dasatinib: a review in chronic myeloid leukaemia and Ph + acute lymphoblastic leukaemia. Drugs. 2017;77(1):85–96.
   PubMed Web of Science ®Google Scholar
• Puszkiel A, Noé G, Bellesoeur A, Kramkimel N, Paludetto M-N, Thomas-Schoemann A, Vidal M, Goldwasser F, Chatelut E, Blanchet B, et al. Clinical pharmacokinetics and pharmacodynamics of dabrafenib. Clin Pharmacokinet. 2019;58(4):451–467.
   PubMed Web of Science ®Google Scholar
• Abdelsalam EA, Abd El-Hafeez AA, Eldehna WM, El Hassab MA, Marzouk HMM, Elaasser MM, Abou Taleb NA, Amin KM, Abdel-Aziz HA, Ghosh P, et al. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. J Enzyme Inhib Med Chem. 2022;37(1):2265–2282.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang W, Hou J, Wang X, Zheng H, Xiong W, Yuan J. Combined effect of tris(2-chloroethyl)phosphate and benzo (a) pyrene on the release of IL-6 and IL-8 from HepG2 cells via the EGFR-ERK1/2 signaling pathway. RSC Adv. 2017;7(85):54281–54290.
   Web of Science ®Google Scholar
• Xu X, Steere RR, Fedorchuk CA, Pang J, Lee J-Y, Lim JH, Xu H, Pan ZK, Maggirwar SB, Li J-D, et al. Activation of epidermal growth factor receptor is required for NTHi-induced NF-κB-dependent inflammation. PLOS One. 2011;6(11):e28216.
   PubMed Web of Science ®Google Scholar
• Kalinowski A, Galen BT, Ueki IF, Sun Y, Mulenos A, Osafo-Addo A, Clark B, Joerns J, Liu W, Nadel JA, et al. Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium. Mucosal Immunol. 2018;11(3):958–967.
   PubMed Web of Science ®Google Scholar
• Huang B-R, Chen T-S, Bau D-T, Chuang I-C, Tsai C-F, Chang P-C, Lu D-Y. EGFR is a pivotal regulator of thrombin-mediated inflammation in primary human nucleus pulposus culture. Sci Rep. 2017;7(1):8578.
   PubMedGoogle Scholar
• Lv P-C, Li D-D, Li Q-S, Lu X, Xiao Z-P, Zhu H-L. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Bioorg Med Chem Lett. 2011;21(18):5374–5377.
   PubMed Web of Science ®Google Scholar
• Wang H-H, Qiu K-M, Cui H-E, Yang Y-S, Xing M, Qiu X-Y, Bai L-F, Zhu H-L. Yin-Luo. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents. Bioorg Med Chem. 2013;21(2):448–455.
   PubMed Web of Science ®Google Scholar
• Al-Salem HS, Arifuzzaman M, Issa IS, Rahman AM. Isatin-hydrazones with multiple Receptor Tyrosine Kinases (RTKs) inhibitory activity and in-silico binding mechanism. Appl Sci. 2021;11:3746.
   Google Scholar
• Aiebchun T, Mahalapbutr P, Auepattanapong A, Khaikate O, Seetaha S, Tabtimmai L, Kuhakarn C, Choowongkomon K, Rungrotmongkol T. Identification of vinyl sulfone derivatives as EGFR tyrosine kinase inhibitor: in vitro and in silico studies. Molecules. 2021;26(8):2211.
   PubMed Web of Science ®Google Scholar
• Abbas HAS, Abd El-Karim SS. Design, synthesis and anticervical cancer activity of new benzofuran–pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. Bioorg Chem. 2019;89:103035.
   PubMed Web of Science ®Google Scholar
• Abd El-Karim SS, Syam YM, El Kerdawy AM, Abdelghany TM. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: synthesis, CDK2 inhibition, QSAR and molecular docking studies. Bioorg Chem. 2019;86:80–96.
   PubMed Web of Science ®Google Scholar
• Thakral S, Saini D, Kumar A, Jain N, Jain S. A synthetic approach and molecular docking study of hybrids of quinazolin-4-ones and thiazolidin-4-ones as anticancer agents. Med Chem Res. 2017;26(8):1595–1604.
   Web of Science ®Google Scholar
• Bhat M, Poojary B, Kalal BS, Gurubasavaraja Swamy PM, Kabilan S, Kumar V, Shruthi N, Alias Anand SA, Pai VR. Synthesis and evaluation of thiazolidinone-pyrazole conjugates as anticancer and antimicrobial agents. Future Med Chem. 2018;10(9):1017–1036.
   PubMed Web of Science ®Google Scholar
• Lv P-C, Zhou C-F, Chen J, Liu P-G, Wang K-R, Mao W-J, Li H-Q, Yang Y, Xiong J, Zhu H-L, et al. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors. Bioorg Med Chem. 2010;18(1):314–319.
   PubMed Web of Science ®Google Scholar
• Fakhry MM, Mahmoud K, Nafie MS, Noor AO, Hareeri RH, Salama I, Kishk SM. Rational design, synthesis and biological evaluation of novel pyrazoline-based antiproliferative agents in MCF-7 cancer cells. Pharmaceuticals. 2022;15(10):1245–1273.
   Web of Science ®Google Scholar
• Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, Golenbock D, Gresnigt MS, Heneka MT, Hoffman HM, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826–831.
   PubMed Web of Science ®Google Scholar
• Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology. 2009;17(2):55–67.
   PubMedGoogle Scholar
• Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002;9(2 Suppl):28–35.
   PubMedGoogle Scholar
• Marchesi VT. From molecular analysis to medical practice: recent studies reveal new therapeutic targets for an old medicine. FASEB J. 1998;12(12):1061–1061.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Abdelgawad MA, Labib MB, et al. Synthesis and biological evaluation of new diarylpyrazole and triarylimidazoline derivatives as selective COX-2 inhibitors. Arch Pharm. 2017;350:1–10.
   Web of Science ®Google Scholar
• Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. J Cell Physiol. 2019;234(5):5683–5699.
   PubMed Web of Science ®Google Scholar
• Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015;15(1):2–7.
   PubMedGoogle Scholar
• Johnson AJ, Hsu A-L, Lin H-P, Song X, Chen C-S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: A plausible link with its anti-tumour effect and cardiovascular risks. Biochem J. 2002;366(Pt 3):831–837.
   PubMedGoogle Scholar
• Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogenesis of breast cancer. WJCO. 2014;5(4):677–692.
   Google Scholar
• Abdellatif KRA, Abdelall EKA, Labib MB, Fadaly WAA, Zidan TH. Design, synthesis of celecoxib-tolmetin drug hybrids as selective and potent COX-2 inhibitors. Bioorg Chem. 2019;90:103029.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Abdelgawad MA, Labib MB, Zidan TH. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of novel triarylpyrazoline derivatives as selective COX-2 inhibitors. Bioorg Med Chem Lett. 2015;25(24):5787–5791.
   PubMed Web of Science ®Google Scholar
• Sharma JN, Jawad NM. Adverse effects of COX-2 inhibitors. ScientificWorldJournal. 2005;5:629–645.
   PubMedGoogle Scholar
• Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1–16.
   PubMed Web of Science ®Google Scholar
• Fu S-L, Wu Y-L, Zhang Y-P, Qiao M-M, Chen Y. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004;10(13):1971–1974.
   PubMed Web of Science ®Google Scholar
• Abuo-Rahma GE-DAA, Abdel-Aziz M, Beshr EAM, Ali TFS. 1,2,4-Triazole/oxime hybrids as new strategy for nitric oxide donors: synthesis, anti-inflammatory, ulceroginicity and antiproliferative activities. Eur J Med Chem. 2014;71:185–198.
   PubMed Web of Science ®Google Scholar
• Abdelhaleem EF, Kassab AE, El-Nassan HB, Khalil OM. Design, synthesis, and biological evaluation of new celecoxib analogs as apoptosis inducers and cyclooxygenase-2 inhibitors. Arch Pharm. 2022;355(11):e2200190.
   PubMed Web of Science ®Google Scholar
• Jeong H-S, Choi HY, Lee E-R, Kim J-H, Jeon K, Lee H-J, Cho S-G. Involvement of caspase-9 in autophagy-mediated cell survival pathway. Biochim Biophys Acta – Mol Cell Res. 2011;1813(1):80–90.
   Web of Science ®Google Scholar
• Abuo-Rahma GE-DAA, Abdel-Aziz M, Mourad MAE, Farag HH. Synthesis, anti-inflammatory activity and ulcerogenic liability of novel nitric oxide donating/chalcone hybrids. Bioorg Med Chem. 2012;20(1):195–206.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Fadaly WAA, Elshaier YAMM, Ali WAM, Kamel GM. Non-acidic 1,3,4-trisubstituted-pyrazole derivatives as lonazolac analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile. Bioorg Chem. 2018;77:568–578.
   PubMed Web of Science ®Google Scholar
• Abdellatif KRA, Fadaly WAA, Kamel GM, Elshaier YAMM, El-Magd MA. Design, synthesis, modeling studies and biological evaluation of thiazolidine derivatives containing pyrazole core as potential anti-diabetic PPAR-γ agonists and anti-inflammatory COX-2 selective inhibitors. Bioorg Chem. 2019;82:86–99.
   PubMed Web of Science ®Google Scholar
• Nobuta T, Hirashima S-i, Tada N, Miura T, Itoh A. One-pot metal-free syntheses of acetophenones from styrenes through aerobic photo-oxidation and deiodination with iodine. Org Lett. 2011;13(10):2576–2579.
   PubMed Web of Science ®Google Scholar
• Omar HA, Arafa E-SA, Salama SA, Arab HH, Wu C-H, Weng J-R. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-κB and MAPK signaling pathways. Toxicol Appl Pharmacol. 2013;272(3):616–624.
   PubMed Web of Science ®Google Scholar
• Nemr MTM, AboulMagd AM, Hassan HM, Hamed AA, Hamed MIA, Elsaadi MT. Design, synthesis and mechanistic study of new benzenesulfonamide derivatives as anticancer and antimicrobial agentsviacarbonic anhydrase IX inhibition. RSC Adv. 2021;11(42):26241–26257.
   PubMed Web of Science ®Google Scholar
• Nakamura JL. The epidermal growth factor receptor in malignant gliomas: Pathogenesis and therapeutic implications. Expert Opin Ther Targets. 2007;11(4):463–472.
   PubMed Web of Science ®Google Scholar
• Cruz-López O, Ner M, Nerín-Fonz F, et al. Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines. J Enzyme Inhib Med Chem. 2021;36:1553–1563.
   PubMed Web of Science ®Google Scholar
• Wang JL, Limburg D, Graneto MJ, Springer J, Hamper JRB, Liao S, Pawlitz JL, Kurumbail RG, Maziasz T, Talley JJ, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 2010;20(23):7159–7163.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265–46272.
   PubMed Web of Science ®Google Scholar
• Aertgeerts K, Skene R, Yano J, Sang B-C, Zou H, Snell G, Jennings A, Iwamoto K, Habuka N, Hirokawa A, et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. J Biol Chem. 2011;286(21):18756–18765.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64:4–17.
   Web of Science ®Google Scholar
• Abdellatif KRA, Abdelall EKA, Labib MB, Fadaly WAA, Zidan TH. Synthesis of novel halogenated triarylpyrazoles as selective COX-2 inhibitors: Anti-inflammatory activity, histopatholgical profile and in-silico studies. Bioorg Chem. 2020;105:104418.
   PubMed Web of Science ®Google Scholar
• Ibrahim ZY, Uzairu A, Shallangwa GA, Abech SE. Pharmacokinetic predictions and docking studies of substituted aryl amine-based triazolopyrimidine designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH). Futur J Pharm Sci. 2021;7(1):113.
   PubMed Web of Science ®Google Scholar